Supplementary MaterialsDocument S1. NHL shown safety?but only limited efficacy of TLR9 agonists.25, 30 These troubles can be, at least partly, ascribed to more recently explained problems in?TLR9 signaling in BCLs. Several studies have linked mutations in?downstream TLR9 signaling (e.g., MYD88) or polymorphism in?the promoter to the pathogenesis of aggressive NHL10, 32 or increased NHL incidence,33… Continue reading Supplementary MaterialsDocument S1. NHL shown safety?but only limited efficacy of TLR9